NICE has recommended belantamab mafodotin for relapsed multiple myeloma, with trial data showing remissions of more than 3 years.
Medscape News UK
Source link : https://www.medscape.com/viewarticle/nice-backs-belantamab-mafodotin-relapsed-myeloma-2026a1000bx0?src=rss
Author :
Publish date : 2026-04-16 15:38:00
Copyright for syndicated content belongs to the linked Source.